Is Avonib/Tosuvo effective in curing myeloid leukemia?

Ivosidenib is an innovative oral drug that targets IDH1 mutations and has received widespread attention in the treatment of acute myeloid leukemia (AML). When many patients hear about this drug, they will be concerned about whether it can really achieve a "cure" effect. In fact, the mechanism of action of ivonib is different from that of traditional chemotherapy. It does not rely on large doses of drugs to quickly kill leukemia cells. Instead, it promotes the gradual recovery of leukemia cell differentiation by inhibiting the abnormal metabolites formed after IDH1 mutation, thereby normalizing hematopoietic function. This method has significantly improved the condition of some patients and extended the time for disease control.

However, strictly speaking, current international mainstream guidelines and research do not define ivonib as a "curative" drug. Leukemia is a complex disease involving multiple genetic mutations and pathways, and it is difficult for a single drug to completely eliminate all abnormal cells. Ivonib is more suitable as a long-term management method, which can significantly delay the progression of the disease, improve symptoms, and even achieve longer-lasting remission in some patients. For people with relapsed or refractory AML, it often brings new treatment opportunities and improves quality of life.

It is worth mentioning that with the development of precision medicine, more and more clinical trials are exploring the value of combining ivonib with other drugs. For example, combination with low-intensity chemotherapy, immune drugs and even other targeted drugs are considered to have the potential to further improve response rates. For some patients with drug resistance or insufficient efficacy, this combination model may become a breakthrough. As research deepens in the future, ivonib may occupy a more central position in treatment strategies.

Reference: https://www.tibsovo.com/